Emyria recently presented its landmark Medibank deal at the Psychedelic Science 2025 conference in Denver, showcasing its leadership in developing innovative mental health care models. The agreement with Medibank provides reimbursement for eligible members with PTSD to access Emyria's psychiatrist-led program. The model highlights how real-world data and collaboration with insurers create sustainable funding pathways. Chief Scientific Officer Dr. Michael Winlo delivered two presentations at the conference, emphasizing Emyria's commitment to advancing mental health treatments. An investor webinar detailing the model will be announced soon. Emyria's integrated approach includes evidence-based treatments, real-world data collection, and the development of new therapies for mental health conditions. Investors can interact with Emyria through the Investor Hub to ask questions and receive updates. It's important to note the cautionary statement on forward-looking statements and risks associated with psychedelic treatments. Emyria continues to drive innovation in mental health care while prioritizing patient safety and efficacy in its treatments. For more information or inquiries, investors can contact Executive Chair Greg Hutchinson.